Novartis AG
SIX:NOVN
Novartis AG
Tax Provision
Novartis AG
Tax Provision Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Tax Provision | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Novartis AG
SIX:NOVN
|
Tax Provision
-$1.7B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-1%
|
|
|
Roche Holding AG
SIX:ROG
|
Tax Provision
-CHf1.7B
|
CAGR 3-Years
16%
|
CAGR 5-Years
12%
|
CAGR 10-Years
6%
|
|
|
S
|
Sandoz Group AG
SIX:SDZ
|
Tax Provision
-$50m
|
CAGR 3-Years
41%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Novartis AG
Glance View
Nestled in the heart of Europe's pharmaceutical landscape, Novartis AG has firmly etched its presence as a beacon of innovation and scientific prowess. This Swiss multinational behemoth, headquartered in Basel, operates at the confluence of research-driven development and cutting-edge technology. At its core, Novartis is devoted to discovering novel therapeutics and delivering them to patients across the globe. The company’s operations span various segments, with Pharmaceuticals and Oncology standing as the pillars of its revenue model. Through these divisions, Novartis vigorously pursues advancements in the treatment of diseases, focusing on areas such as cardiovascular, immunology, neuroscience, respiratory, and oncology. The innovative medicines they develop emerge from robust pipelines bolstered by strategic investments in research and development, propelling them to the forefront of healthcare innovation. Moreover, Novartis leverages a synergy between its Sandoz division, which is known for a strong generics and biosimilars portfolio, and its advanced therapeutic areas in Pharmaceuticals. This duality not only makes the company versatile but also resilient in the face of market volatilities. Unlike many pharmaceutical giants, Novartis prioritizes a hybrid approach by combining cutting-edge biotechnology with a stronghold in cost-effective generics. This model allows Novartis to cater to both the high-margin, innovation-driven segments and the volume-based, lower-margin arenas. Ultimately, their strategic focus is not just on creating the next blockbuster drug but on improving access to healthcare solutions globally, thereby reinforcing its revenue engine while delivering on its mission to reimagine medicine.
See Also
What is Novartis AG's Tax Provision?
Tax Provision
-1.7B
USD
Based on the financial report for Dec 31, 2024, Novartis AG's Tax Provision amounts to -1.7B USD.
What is Novartis AG's Tax Provision growth rate?
Tax Provision CAGR 10Y
-1%
Over the last year, the Tax Provision growth was -209%. The average annual Tax Provision growth rates for Novartis AG have been -2% over the past three years , 1% over the past five years , and -1% over the past ten years .
You don't have any saved screeners yet